GÖTEBORG, Sweden--(BUSINESS WIRE)-- Regulatory News:
Meda’s (STO:MEDAA) partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.
“This is a milestone for retigabine and our partnership with Valeant”, said Anders Lönner, CEO Meda AB.
Valeant has a collaboration agreement with the pharmaceutical company GlaxoSmithKline for the global commercialization of retigabine. Meda is entitled to receive royalties of between 6 - 8 percent on retigabine sales.
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This information was brought to you by Cision http://www.cisionwire.com
Anders Larnholt, Vice President Corporate Development & IR
ph: 46 709-458 878
KEYWORDS: Europe Sweden
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical